CRNDE can promote CRC development by epigenetically suppressing the expressions of dual-specificity phosphatase 5 (DUSP5) and cyclin-dependent kinase inhibitor 1A (CDKN1A) [301]. This evidence concerns the gene DUSP5 and colorectal carcinoma.